BLRX Stock Overview
BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
BioLineRx Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.58 |
| 52 Week High | ₪2.53 |
| 52 Week Low | ₪0.59 |
| Beta | 0.93 |
| 1 Month Change | -44.15% |
| 3 Month Change | -50.41% |
| 1 Year Change | -46.48% |
| 3 Year Change | -81.14% |
| 5 Year Change | -89.77% |
| Change since IPO | -99.31% |
Recent News & Updates
Recent updates
BioLineRx stock slips on $15M securities offering
Sep 19BioLineRx files for FDA approval of motixafortide in stem cell mobilization
Sep 12biolinerx GAAP EPS of -$0.01 beats by $0.08
Aug 16BioLineRx, GenFleet to co-develop Motixafortide treatment for a type of pancreatic cancer
Jun 29BioLineRx: A Top Candidate For A Takeover Before 2022 Ends
Jun 30biolinerx EPS beats by $0.17
May 26BioLineRx (BLRX) shares rocket 73% on positive Motixafortide data in multiple myeloma
May 04BioLineRx jumps 22% on promising triple combination data of motixafortide in pancreatic cancer
Dec 16biolinerx EPS beats by $0.32
Nov 23BioLineRx launches early-stage study with lead asset in COVID-19 related respiratory distress
Nov 18BioLineRx launches mid-stage combo study in first-line pancreatic cancer
Oct 29Shareholder Returns
| BLRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.1% | 1.0% | 1.2% |
| 1Y | -46.5% | 0.7% | 24.9% |
Return vs Industry: BLRX underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: BLRX underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| BLRX volatility | |
|---|---|
| BLRX Average Weekly Movement | 13.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BLRX's share price has been volatile over the past 3 months.
Volatility Over Time: BLRX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 79 | Phil Serlin | www.biolinerx.com |
BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions.
BioLineRx Ltd. Fundamentals Summary
| BLRX fundamental statistics | |
|---|---|
| Market cap | US$52.61m |
| Earnings (TTM) | -US$60.61m |
| Revenue (TTM) | US$4.80m |
11.0x
P/S Ratio-0.9x
P/E RatioIs BLRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLRX income statement (TTM) | |
|---|---|
| Revenue | US$4.80m |
| Cost of Revenue | US$3.69m |
| Gross Profit | US$1.11m |
| Other Expenses | US$61.72m |
| Earnings | -US$60.61m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.051 |
| Gross Margin | 23.08% |
| Net Profit Margin | -1,262.79% |
| Debt/Equity Ratio | 73.9% |
How did BLRX perform over the long term?
See historical performance and comparison